EpiVax launches AI-enhanced immunogenicity prediction models

jp.prnasia.com (Japanese)

EpiVax announced AI-enhanced upgrades to its ISPRITM platform for assessing biopharmaceutical immunogenicity risk, introducing updated models on September 3, 2026. The release includes JanusMatrixTM 2.1, which uses AI to improve immune tolerance prediction, and a new JanusMatrix-Adjusted EpiMatrix (JAX) score designed to better align with clinically observed immunogenicity. An enhanced ADA 2.2 prediction model, trained on diverse clinical monoclonal antibodies, shows stronger correlation with real-world data. These enhancements align with FDA initiatives promoting new approach methodologies, helping sponsors identify immunogenicity risks, protect asset value, and reduce development program risks.


With a significance score of 2.2, this news ranks in the top 18% of today's 31231 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


EpiVax launches AI-enhanced immunogenicity prediction models | News Minimalist